NewsOne Year Extension To France's Medical Cannabis Trial Makes...

One Year Extension To France’s Medical Cannabis Trial Makes Its Way Through Parliament


As reported in

LAST month France’s Directorate General of Health (DGS) pushed ahead with plans to extend the country’s medical cannabis trial by a minimum of one year without waiting for the results of the trial to be submitted to parliament. 

This move was widely condemned by patient groups, who were only informed of the decision after a press release was leaked from representatives of the agro-industrial sector, who were initially consulted. 

The decision also left two points to be clarified – the pharmaceutical status of these products and whether or not they will be reimbursed by health insurance. 

It also left many questions around budgetary indications for the postponement of the experiment. Since the 3,000 patient target for the experiment had not been reached, the current suppliers of medical cannabis could be offered to continue to supply their products free of charge. A “lightening” of the device was also mentioned, without further details.

Social Security Financing Bill

The extension of medical cannabis trials, although desired by the Ministry of Health, is now being played out within the framework of the Social Security Financing Bill (PLFSS), which is understood to determine how the country’s social security income is allocated. 

Several amendments were tabled by the various parliamentary groups making up the committee.

  • The Europe Ecologie Les Verts (EELV) party proposed four separate amendments. The legalisation of recreational cannabis, an experiment in the legalisation of recreational cannabis, the generalisation of medical cannabis or the extension of the experiment for one year. The first three were deemed inadmissible, the last was rejected.
  • A cross-partisan group led by Caroline Janvier proposed the extension of the experimentation of medical cannabis for one year with the obligation for the Ministry of Health to work on “the conditions of production and distribution of medical cannabis as well as on the advisability of its reimbursement. The amendment was rejected.
  • Horizons proposed extending the experiment for 3 years. The amendment was adopted.
  • Loiret MEP Stéphanie Rist, rapporteur for the Commission, tabled a sub-amendment proposing a one-year extension. The sub-amendment was carried .

The amendment, which will be debated in France’s parliament, will therefore propose extending the experiment for a year.

To our knowledge, no budget has been allocated for this extension. There are also no obligations for the government to generalise medical cannabis at the end of the possible extension. 

Furthermore, the ministry does not commit to the construction of the conditions for the production and distribution of medical cannabis in France in the meantime, or to consider the reimbursement issue. 

If the proposed amendment was not voted on during its study in the assembly, from our understanding, the trial would stop without generalisation.

The statement of the adopted sub-amendment explains that the experiment “has not yet been able to produce sufficient clinical results for us to be able to decide on its generalisation. 

It is worth noting that the purpose of the medical cannabis trial was not to produce clinical results but “to evaluate, in a real situation, the recommendations of the committee in terms of prescribing and dispensing conditions and the adherence of health professionals and patients to these conditions” according to the National Agency for the Safety of Medicines (ANSM).

Latest news

European Cannabis Stocks Review: Celadon Shares Spike 150% On Licence Update, OCT Continues Recovery, & Creso Pharma Censured By ASX

Celadon Pharmaceuticals  Celadon Pharmaceuticals stock has skyrocketed by more than 150% this week following the announcement that its current Home...

Benefits of F1 Cannabis Hybrids from Royal Queen Seeds

F1 hybrids have revolutionised the way we grow and use plants. Now, F1 cannabis seeds are bringing growers, smokers,...

Celadon Pharmaceuticals Announces Home Office Approval Of Licence For Commercial Sale Of GMP Cannabis

PRESS RELEASE FURTHER to the announcement dated 16 January 2023, Celadon Pharmaceuticals Plc (AIM: CEL), a UK-based pharmaceutical company focused on...

Proposed Changes To Germany’s Medical Cannabis Framework Would ‘Seriously Impact Both Patients And Industry’ If Brought In Tomorrow

TOMORROW, Germany’s Federal Joint Committee (G-BA) is expected to announce major changes to the country’s medical cannabis framework.  These could...

Will Twitter’s ‘Relaxation’ On Cannabis Advertising Help Break The Industry’s Social Media Ad Embargo?

TWITTER has become the first major social media platform to openly allow the advertisement of cannabis brands.  Since the new...

Kanabo Launches New Online Medical Cannabis Clinic ‘Treat It’, Offering Access To Doctors In ‘Less Than 24 Hours’

KANABO Group has today announced the launch of a new online medical cannabis clinic for pain management, Treat It.  The...

Must read

You might also likeRELATED
Recommended to you